Células madre
Los inhibidores de células madre son compuestos que actúan específicamente sobre las células madre y sus vías de señalización, afectando su capacidad para autorrenovarse y diferenciarse. Estos inhibidores son cruciales en la investigación centrada en controlar el comportamiento de las células madre, comprender los procesos de desarrollo y desarrollar terapias para enfermedades como el cáncer, donde se cree que las células madre juegan un papel clave. En CymitQuimica, ofrecemos una variedad de inhibidores de células madre para apoyar su investigación en medicina regenerativa, biología del desarrollo y oncología.
Se han encontrado 486 productos de "Células madre"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
RBPJ Inhibitor-1
CAS:<p>RBPJ Inhibitor-1 (RIN1), a compound that impedes the functional interaction between RBPJ and SHARP, effectively inhibits NOTCH-dependent tumor cell</p>Fórmula:C17H14FN3O2Pureza:99.58%Forma y color:SoildPeso molecular:311.31ROCK2-IN-9
<p>ROCK2-IN-9 (compound 7u), a selective ROCK2 inhibitor with an IC50 value of 36.8 nM, demonstrates anticancer properties by impeding cancer cell migration and invasion. This action is achieved through the regulation of various actin cytoskeleton cellular activities. It holds potential for use in breast cancer research.</p>Fórmula:C28H30N8O2Forma y color:SolidPeso molecular:510.59Cirevetmab
CAS:<p>Cirevetmab (ZTS-00521426), a caninized monoclonal antibody targeting Canis lupus familiaris TGFB1, is classified as an immunoglobulin G2-kappa.</p>Forma y color:LiquidLerdelimumab
CAS:<p>Lerdelimumab (CAT-152) is an IgG4 monoclonal antibody targeting TGF-β2, used in glaucoma scarring research.</p>Forma y color:LiquidGSK-3β inhibitor 19
<p>GSK-3β Inhibitor 19 (compound 36) is an inhibitor of GSK-3β with an IC50 value of 70 nM. It is applicable in research related to anti-inflammatory and Alzheimer's disease.</p>Fórmula:C15H12N4O2SForma y color:SolidPeso molecular:312.35STAT3-IN-34
<p>STAT3-IN-34 (Compound 15E) acts as a STAT3 inhibitor, blocking both the nuclear translocation and the transcriptional regulator activity of STAT3. It effectively inhibits HaCaT cell proliferation with an IC50 value of 0.008 μM. Additionally, STAT3-IN-34 reduces IL-17A expression and mitigates Imiquimod-induced psoriasis in mouse models.</p>Fórmula:C19H16N2O4SForma y color:SolidPeso molecular:368.41YAP-IN-1
<p>YAP-IN-1 (Compound (+)-1) is an autophagy inhibitor specifically targeting YAP1. It binds to the Hippo pathway transcription factor YAP1 with a Kd of 9.13 μM, promoting its degradation through the chaperone-mediated autophagy (CMA) pathway. This process inhibits the Rab7-mediated fusion of autophagosomes with lysosomes and decreases autophagy levels without affecting lysosomal function. YAP-IN-1 shows potential for cancer research, including in hepatocellular carcinoma and breast cancer.</p>Forma y color:Odour SolidRipasudil free base
CAS:<p>Ripasudil free base (K-115 (free base)) is a selective and potent ROCK inhibitor, is a novel and potent antiglaucoma agent.</p>Fórmula:C15H18FN3O2SPureza:98%Forma y color:SolidPeso molecular:323.39PROTAC YAP degrader-1
<p>PROTAC YAP degrader-1, a targeted proteolysis promoting chimeric molecule, both degrades the YAP protein and inhibits its nuclear localization. This compound is formulated with Demethyl-NSC682769 as the target protein ligand, and utilizes (R,S,R)-AHPC-PEG2-C2-boc, which is the E3 ubiquitin ligase ligand + Linker conjugate. The linker incorporated in the design is Acid-PEG2-C2-Boc.</p>Fórmula:C56H62N6O9SForma y color:SolidPeso molecular:995.19GSK-3β inhibitor 1
CAS:<p>GSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy.</p>Fórmula:C14H10N2OPureza:99.40%Forma y color:SolidPeso molecular:222.24P17 Peptide
CAS:<p>P17 Peptide, a human TGF-β1 inhibitory peptide, effectively blocks the activity of woodchuck TGF-β1.</p>Fórmula:C95H139N27O21Forma y color:SolidPeso molecular:1995.29Epigenetics Compound Library
<p>Well-chosen 953 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new</p>Forma y color:Odour SolidCBT-295
<p>CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-β, TNF-α, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compound's ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.</p>Fórmula:C18H20ClN3OForma y color:SolidPeso molecular:329.82STAT3-IN-31
<p>STAT3-IN-31 (compound K2071), derived from STATtic, acts as an inhibitor of both STAT3 and mitotic processes. This compound interrupts mitotic progression and impacts the formation of the mitotic spindle. Additionally, STAT3-IN-31 hampers migration in glioblastoma cells, suppresses cellular proliferation within tumor spheroids, induces senescence in glioblastoma, and inhibits the growth of Temozolomide-resistant cells while reducing the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein (MCP-1).</p>Fórmula:C16H15NO3SForma y color:SolidPeso molecular:301.36HC-258
CAS:<p>HC-258 is a direct TEAD inhibitor covalent Cys380, and reduces the transcriptional levels and inhibits the migration of CTGF, CYR61, AXL and NF2 MDA-MB-231.</p>Fórmula:C20H24N2O2Forma y color:SolidPeso molecular:324.42TGFβRI-IN-7
<p>TGFβRI-IN-7 (compound 16W) is a potent inhibitor of TGFβRI. It effectively inhibits the phosphorylation of SMAD2/3 and reduces the viability of H22 cells, with IC50 values of 12 nM and 65 nM, respectively. In an H22 cell xenograft model, TGFβRI-IN-7 exhibits antitumor efficacy with a TGI of 79.6%.</p>Fórmula:C27H32N6O2Forma y color:SolidPeso molecular:472.582WAY-297174
CAS:<p>WAY-297174 is a human protein kinase CK2 inhibitor with IC50 of > 33 μM.</p>Fórmula:C11H12N2O2S2Pureza:99.53%Forma y color:SoildPeso molecular:268.36TEAD-IN-19
<p>TEAD-IN-19 (Compound 1l) is a transcriptional inhibitor of TEAD, showing inhibition rates of 38.5%, 36.2%, 57.8%, and 71.3% for TEAD1, TEAD2, TEAD3, and TEAD4, respectively, at 10 μM. It exhibits strong antiproliferative and antimigratory effects on prostate cancer cell lines and significantly reduces the expression of TEAD-regulated downstream genes. TEAD-IN-19 holds potential for research in the field of cancer therapeutics.</p>Forma y color:Odour SolidWnt/Hedgehog/Notch Compound Library
<p>A unique collection of 237 Wnt/Hedgehog/Notch signaling targeted compounds for high throughput and high content screening;</p>Forma y color:Odour SolidLX-7101 hydrochloride
CAS:<p>LX-7101 hydrochloride is a potent LIMK and ROCK2 inhibitor with antihypertensive activity, inhibits LIMK1/2, ROCK, PKA, and can be used to study glaucoma.</p>Fórmula:C23H29N7O3xHClPureza:98.96%Forma y color:SolidPeso molecular:487.99
